The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.

Alphabet early-stage investment unit GV has added two biotechnology professionals, Dan Lynch and Mojca Skoberne, to its team.

Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

CSIRO-founded Main Sequence Ventures has pocketed $194m for its second fund, which has added decarbonisation to the firm’s list of targeted technologies.

Less than two months after closing a $100m series C round, the Dundee spinout has raised $225m in a series D led by SoftBank Vision Fund 2.

Lilly Asia Ventures co-led a $61.7m round for the endoscopy technology developer that was also backed by Medtronic.

Renal care provider InterWell Health and skincare product manufacturer Make Essence both raised approximately $46m while Salesforce-backed JazzHR agreed a merger.

Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.